05.07.26 BY ALEXANDRE STIPANOVICH
Now that ibogaine and methylone join MDMA and psilocybin as potential treatments for PTSD, let's try to understand the pharmacology of how each of these compounds accesses and reprocesses trauma. MDMA, ibogaine, psilocybin, and methylone are four pharmacologically distinct compounds which produce durable reductions in PTSD symptoms, though for ibogaine and methylone the clinical evidence remains early stage. None work like antidepressants. None require daily dosing. None do the same thing at the receptor level. Yet they converge on a common outcome: the reprocessing of traumatic memory. Let's close our series with psilocybin.
Psilocybin is dephosphorylated to psilocin in the liver, which then acts as a selective partial agonist at 5-HT2A receptors, the defining mechanism of classical psychedelics. These receptors sit at the top of the cortical processing hierarchy, concentrated in layer V pyramidal neurons of the prefrontal cortex, where they regulate how the brain weighs incoming information against existing beliefs (Stoliker D. et al., 2022).
The brain normally generates strong top-down predictions that suppress sensory noise and maintain stable interpretive frameworks, including the rigid fear-based narratives that define PTSD. 5-HT2A activation disrupts this architecture at two levels. At the cortical level, it drives a glutamate surge through both direct excitation of layer V pyramidal neurons and increased glutamate release from thalamocortical afferents. At the subcortical level, it weakens the thalamic gate, a shell of inhibitory neurons (the reticular nucleus) that normally filters what sensory and associative information reaches cortex. The combined effect is that signals previously suppressed by the brain's predictive model now reach cortex unchecked, while the top-down predictions that would ordinarily override them lose their grip. At sufficient doses, this process produces ego dissolution, the temporary collapse of the self-referential cognitive architecture through which traumatic priors are maintained (Modlin NL et al., 2025).
Ego dissolution is neurally reflected as suppression of the default mode network, the circuit underlying self-referential processing and rumination, with concurrent increases in connectivity between brain networks that are normally segregated (Vollenweider and Preller, 2020). Preclinical data confirm the 2A receptor dependence of these effects: 5-HT2A antagonism eliminates psilocybin's enhancement of fear extinction, extinction retention, and suppression of fear renewal (Woodburn SC et al., 2024).
“Psilocybin dissolves the top-down cognitive architecture that maintains rigid traumatic priors, allowing structural reorganization from the ground up.”
Unlike MDMA, psilocybin does not require directed engagement with specific traumatic content during the acute session. The dissolution itself is the mechanism: disrupting the cognitive structure that organizes and maintains fear, then opening a window of neuroplasticity in which new structures can form. That window has a defined neurobiology: 5-HT2A-driven BDNF/TrkB signalling and mTOR pathway activation induce a transient period of enhanced synaptic plasticity, including dendritic spine growth and increased structural connectivity, that outlasts drug clearance by days to weeks (Vollenweider and Preller, 2020). The therapeutic process that follows is integration: structured sessions in which the patient, working with a therapist, consolidates new perspectives, reprocesses traumatic material from the destabilised state, and constructs alternative cognitive frameworks to replace the rigid architecture that psilocybin disrupted. Preclinical evidence suggests this process is not passive. Psilocybin enhances fear extinction only when administered concurrently with extinction exposure, not before conditioning or after extinction alone, indicating that active therapeutic engagement during or immediately following the plasticity window is necessary for durable effects (Woodburn SC et al., 2024).
Three Pathways, One Lock
The contrast across these three parts is clarifying. Noribogaine produces autonomous, dissociated replay of autobiographical memory through NMDA antagonism and κ agonism, sustained by a GDNF autocrine loop that extends the therapeutic window hours beyond drug clearance. MDMA suppresses amygdala-mediated fear during directed, therapist-guided memory processing, enabling safe retrieval and reconsolidation. Psilocybin dissolves the top-down cognitive architecture that maintains rigid traumatic priors, opening a neuroplasticity window in which integration therapy enables structural reorganisation from the ground up.
All three converge on memory reconsolidation as the likely therapeutic principle. But the entry point is different for each. Noribogaine enters through dissociation and neurotrophic reorganisation. MDMA enters through fear suppression and guided access. Psilocybin enters through dissolution of the cognitive structure that organises fear in the first place.
For PTSD, this heterogeneity matters clinically. Different patients, different trauma profiles, and different therapeutic contexts may be differentially responsive to each pathway. The field tends to ask which compound works best. The more precise question is which mechanism of memory access fits a given patient's neurobiology and the nature of their traumatic encoding.
References
- Stoliker D, Egan GF, Friston KJ, Razi A. Neural Mechanisms and Psychology of Psychedelic Ego Dissolution. Pharmacol Rev. 2022;74(4):876–917.
- Modlin NL, Williamson V, Maggio C, Stubley J, Kirlic N, Cleare A, Rucker J. Clinical conceptualisation of PTSD in psilocybin treatment: disrupting a pre-determined and over-determined maladaptive interpretive framework. Ther Adv Psychopharmacol. 2025;15:20451253251342319.
- Vollenweider FX, Preller KH. Psychedelic drugs: neurobiology and potential for treatment of psychiatric disorders. Nat Rev Neurosci. 2020;21(11):611–624.
- Woodburn SC, Levitt CM, Koester AM, Kwan AC. Psilocybin facilitates fear extinction: importance of dose, context, and serotonin receptors. ACS Chem Neurosci. 2024;15(16):3034–3043.
